Franck Mortreux
  • E-mail :[email]
  • Phone : +33 4 72 72 86 63
  • Location : Lyon, France
Last update 2021-02-18 12:14:49.255

Franck Mortreux RNA processing during HTLV-1 associated leukemogenesis

Course and current status

Since 2010 : INSERM scientist at Laboratory of Biology and Modeling of the Cell (LBMC), Ecole Normale Supérieure de Lyon, Lyon (France)

2008 : HDR, Université de Lyon 1

2003-2010 : INSERM Scientist at Centre Léon Berard, Lyon, France. Eric Wattel's lab

2001-2002 : Post-doc at the Fusagx Gembloux (Belgium). Luc Willems' Lab

1997-2001 : PhD in Fondamental Virology, Université Paris 7 (France). 

Scientific summary

My work focuses on molecular mechanism that regulates leukemogenic processes during the infection by HTLV-1, the causative agent of the adult T-cell leukemia/lymphoma (ATLL) and various inflammatory diseases. I initiated these works during my PhD with Eric Wattel at the Institut de Recherche sur le Cancer de Lille (IRCL, France). In particular, we evidenced that HTLV-1 replicates via the clonal expansion of infected cells in a context of cellular genomic instability that contributes to the outcome of ATLL and the genomic diversity of HTLV-1. These findings were further confirmed and extended to the Bovine Leukemia Virus during my postdoctoral internship in Luc Willems’ lab at FUSAgs Gembloux (Belgium). 

I joined INSERM in 2002 and I pursued my work in Lyon (France) in the Centre Léon Bérard (CRCL), where I created my own group in the E. Wattel's team. I obtained my HDR in 2008. During the next 3 years, my activities focused on molecular mechanisms involved in the viral persistence of HTLV-1 and other deltaretroviruses (HTLV-II and BLV) by deciphering how viruses hijack cellular processes to reprogram gene expression. In particular, our work has uncovered mechanisms by which HTLV-1 promotes transcriptional changes involved in telomere maintenance. In 2011, my group joined the Laboratory of Biology and Modeling of the Cell (LBMC) at ENS-Lyon where I initiated studies evaluating post-transcriptional regulations upon HTLV-1 infection, including miRNA expression and alternative splicing of coding-RNAs. I was also involved in translational research (CHRT INSERM) with the Hospices Civils de Lyon. In this framework, we defined alternative splicing modifications as potent prognostic markers in acute myeloblastic leukemia. 

At the methodological level, my group has implemented various approaches including limited-dilution cloning of primary T-CD4+ cells, large-scale analysis of gene expression both at the whole transcript and exon levels, microRNA quantification assays (chips and TLDA), mass spectrometry analysis of transcription factors using DNA affinity precipitation assays (DAPA), and more recently, tools for assessing changes in 3D chromatin conformation (Hi-C, 3C and 4C). 

My current projects focus on molecular mechanisms linking the chromatin topology to alternative splicing decisions involved in synthesis of linear and circular isoforms of RNAs during the HTLV-1-associated leukemogenesis. 

Image d’exemple